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PURPOSE: To determine whether volumetric changes of enhancement as seen on contrast-enhanced magnetic
resonance (MR) imaging can help assess early tumor response and predict survival in patients with metastatic
uveal melanoma after one session of transarterial chemoembolization (TACE). MATERIALS AND METHODS:
Fifteen patients with 59 lesions who underwent MR imaging before and 3 to 4 weeks after the first TACE were
retrospectively included. MR analysis evaluated signal intensities, World Health Organization (WHO), Response
Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL), modified
RECIST (mRECIST), tumor volume [volumetric RECIST (vRECIST)], and volumetric tumor enhancement
[quantitative EASL (qEASL)]. qEASL was expressed in cubic centimeters [qEASL (cm3)] and as a percentage of
the tumor volume [qEASL (%)]. Paired t test with its exact permutation distribution was used to compare
measurements before and after TACE. The Kaplan-Meier method with the log-rank test was used to calculate
overall survival for responders and non-responders. RESULTS: In target lesions, mean qEASL (%) decreased from
63.9% to 42.6% (P = .016). No significant changes were observed using the other response criteria. In non-target
lesions, mean WHO, RECIST, EASL, mRECIST, vRECIST, and qEASL (cm3) were significantly increased compared
to baseline. qEASL (%) remained stable (P= .214). Median overall survival was 5.6months. qEASL (cm3) was the only
parameter that could predict survival based on target lesions (3.6 vs 40.5 months, P b .001) or overall (target and non-
target lesions) response (4.4 vs 40.9 months, P= .001). CONCLUSION: Volumetric tumor enhancement may be used
as a surrogate biomarker for survival prediction in patients with uveal melanoma after the first TACE.
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Table 1. Baseline Patient Characteristics
Characteristic Value (%)
No. of Patients 15 (100)
Sex
Female 8 (53.3)
Male 7 (46.7)
Age*
All patients 63 (11.2) [range, 46-83]
Female 59 (10.8) [range, 46-82]
Male 69 (9.8) [range, 57-83]
Ethnicity
White 15 (100)
Eye treatment
Enucleation 6 (40)
Radioactive plaque 5 (33.3)
Radioactive plaque + enucleation 3 (20)
Radiotherapy 1 (6.7)
Biopsy-proven liver metastasis 15 (100)
Tumor number liver lesions
10-20 3 (20)
N20 12 (80)
Extrahepatic disease 11 (73.3)
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Uveal melanoma is the most common primary intraocular malignant
tumor in adults [1]. It is a rare disease with an incidence of 5.1 per
million in the United States [2]. The 5-year survival rate ranges from
77% to 84% [2,3]. Unlike cutaneous melanoma that has a
widespread metastatic pattern [4], uveal melanoma has a significant
predilection for metastasis to the liver [5]. Approximately 50% of the
patients will develop metastatic liver disease. Although there are
effective local therapies to eliminate and prevent recurrence within the
eye (radioactive plaque, proton beam, enucleation), there are no
effective systemic therapies for metastatic uveal melanoma [6]. As the
liver is the first and, in many cases, the only site for metastatic disease,
new modalities of therapy, including the use of regional therapies
such transarterial chemoembolization (TACE), have been used.
The clinical course is highly dependent on disease progression
within the liver. Once diagnosed with liver metastasis, the prognosis is
dismal with a median survival of 2 months for patient receiving no
treatment and 5 to 7 months for patients who received therapy [7,8].
Thus, determining the response to TACE early after the locoregional
treatment is crucial to guide the course of therapy.
Overall survival is the ultimate end point in clinical cancer research.
However, most clinical trials rely on imaging criteria as a surrogate for
survival [9]. For the purpose of radiologic response evaluation, the
World Health Organization (WHO) response criteria were intro-
duced in 1979. The WHO criteria are based on the sum of the
product of bidimensional diameters of the lesions [10]. To address
some limitations of the WHO criteria, the Response Evaluation
Criteria in Solid Tumors (RECIST) was introduced in 2000 [11] and
was revised to version 1.1 in 2009 [12]. RECIST is based on the sum
of the unidimensional longest diameters. Both WHO criteria and
RECIST were designed to evaluate systemic chemotherapy in which
all tumors are equally exposed to systemic agents and address
shrinkage of tumor size. In the case of locoregional therapy such as
TACE, clinical benefit is not always correlated with tumor shrinkage
but could be paralleled with necrosis of a viable tumor. Because the
WHO criteria and RECIST are based on tumor size measurements,
they do not address antitumor activity such as necrosis. Therefore, in
response to these concerns, the European Association for the Study of
the Liver (EASL) recommended measuring changes in the area of
tumor enhancement [13]. More recently, the American Association
for the Study of Liver Disease proposed an amendment of RECIST
[modified RECIST (mRECIST)] to take into consideration changes
in tumor enhancement as a biomarker of tumor viability [14].
It has been acknowledged that assessing treatment response using
volumetric measurements should be a priority [14]. Prior studies
showed the value of volumetric assessment in determining tumor
response after intraarterial therapies [15–17].
The objective of this study was to determine whether quantitative
volumetric changes as seen on contrast-enhanced magnetic resonance
(MR) imaging can help assess early tumor response and predict
survival in patients with metastatic uveal melanoma after one session
of TACE.Eastern Cooperative Oncology Group performance status
Grade 0 9 (60)
Grade 1 6 (40)
Child-Pugh class
A 15 (100)
Patent portal vein 15 (100)
Note: Except where indicated, data represent number of patients and numbers in parentheses
are percentages.
*Data are represented as means ± standard deviation.Materials and Methods
This was a single-institution retrospective study. The study was
compliant with the Health Insurance Portability and Accountability
Act and was approved by the Institutional Review Board. Informed
consent was waived.Study Design
A review of the database of prospectively enrolled patients with
uveal melanoma who underwent TACE at our institution from 2004
to 2014 was performed. A total of 21 patients were identified.
Inclusion criteria were given as follows: 1) diagnosis of livermetastasis
confirmed by means of biopsy; 2) absence of previous systemic
chemotherapy and/or liver directed therapies that might influence
tumor response; 3) patients who underwent dynamic contrast-
enhanced MR imaging before and approximately 3 to 4 weeks after
TACE; 4) an Eastern Cooperative Oncology Group performance status
of up to 2; 5) additional criteria included Child-Pugh class; unifocal or
multifocal hepatic malignancy; absent or limited extrahepatic malig-
nancy; absent or trace ascites; albumin level of more than 2.5 g/dl;
alanine aminotransferase and aspartate aminotransferase levels of less
than five times the upper normal limit; total serum bilirubin level of less
than 3.0 mg/dl; serum creatinine level of less than 2.0 mg/dl; platelet
count of at least 50,000/mm3; international normalized ratio of up to
1.5; at least partial patency of the portal venous system. Six patients were
excluded for the following reasons: previous systemic and/or
locoregional therapies (n = 1) and absence of follow-up MR imaging
after TACE (n = 5). On the basis of these criteria, the final study
population included 15 patients. Baseline characteristics are summa-
rized in Table 1.
TACE Protocol
All patients considered for TACE were discussed at our
multidisciplinary liver tumor board. All TACE procedures were
performed by one experienced interventional radiologist with 16 years
of experience by using a consistent approach as reported previously
[18]. Briefly, an 18-gauge single-wall needle was used with the
Seldinger technique to access the right common femoral artery. A 5-F
vascular sheath was placed over a 0.035-inch Bentson guidewire
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Simmons-1 catheter (Cordis, Miami Lakes, FL) was advanced over
the wire and reformed into the aortic arch and used to select the celiac
axis. Then, a Renegade HI-FLO microcatheter was advanced over a
Fathom-16 wire (Boston Scientific, Natick, MA) into the desired
hepatic artery branch, depending on the tumor location. Selective
catheterization was performed to achieve lobar or sub-/segmental
embolization based on the targeted lesions. A solution containing 50
mg of doxorubicin and 10 mg of mitomycin C in a 1:1 mixture with
iodized oil (Lipiodol; Laboratoire Guerbet, Aulnay-sous-Bois, France)
was infused and followed by 100- to 300-μm diameter microspheres
(Embospheres; Merit Medical Systems, South Jordan, UT).
Substantial arterial flow reduction to the tumor was defined as the
technical end point of embolization; complete occlusion of the
tumor-feeding blood vessels was avoided to maintain the arterial
pathway for potential retreatment.
MR Imaging Protocol
MR imaging was performed at baseline and 3 to 4 weeks after the
initial TACE by using a 1.5-T superconducting MR system (GE Signa;
GEMedical Systems, Milwaukee, WI) and a phased-array torso coil for
signal reception. The protocol included 1) axial T2-weighted fast spin-
echo images (repetition time/echo time, 5000/100milliseconds; matrix
size, 256 × 256; section thickness, 8 mm; intersection gap, 2 mm;
receiver bandwidth, 32 kHz), 2) axial T1-weighted dual fast gradient-
recalled echo sequence, and 3) axial breath-hold unenhanced and
contrast-enhanced [0.1 mmol per kilogram of body weight of
intravenous gadodiamide (Omniscan; GE Healthcare, Princeton,
NJ)] T1-weighted three-dimensional fat-suppressed spoiled gradient-
recalled echo images (5.1/1.2; field of view, 320-400 mm; matrix size,
192 × 160; section thickness, 4-6 mm; receiver bandwidth, 64 kHz; flip
angle, 15°) in the arterial, portal venous, and equilibrium phases
(20 seconds, 60-70 seconds, and 180-200 seconds after intravenous
contrast material injection, respectively).
MR Image Analysis
Quantitative volumetric image analysis was performed by a
radiologist (with 7 years of experience). Tumor response assessment
was conducted by two radiologists (with 7 and 9 years of experience)
during the same reading session to ensure careful comparison of
pretreatment and posttreatment findings. Any discrepancy was
resolved by consensus.
For each patient, 2 lesions in the treated lobe of the liver (target
lesions) and 2 lesions in the untreated lobe (non-target lesions) were
evaluated [30 target and 29 non-target lesions (one patient had only
one non-target lesion); a total of 59 lesions]. Lesions had a minimum
diameter of 1 cm. To ensure independent sampling, the two largest
lesions were evaluated in each lobe of the liver.
The signal intensity of all the target and non-target lesions was
graded on T2-weighted and T1-weighted images as isointense,
hypointense, or hyperintense in relation to normal liver tissue. High
signal intensity lesions on T2-weighted images were also compared to
the spleen. In heterogeneous lesions on T2- and T1-weighted images
(e.g., with areas of hypointensity and hyperintensity), the lesions were
deemed isointense, hypointense, or hyperintense depending on the
most prevalent signal in each respective lesion. In cases of lesions that
had hyperintense signal intensities in relation to the liver tissue on
unenhanced T1-weighted images, subtraction was performed to assess
tumor enhancement.Quantitative Volumetric Image Analysis. Quantitative volumetric
image analysis was performed using a semiautomatic three-dimen-
sional (3D) software prototype (Medisys; Philips Research, Suresnes,
France), as described in detail previously [19,20]. Briefly, a
semiautomatic 3D segmentation mask was generated on the 20-
second contrast-enhanced MR images (arterial phase) obtained before
and after TACE (Figure 1, A and B). The arterial phase was chosen
because all the lesions of the study population demonstrated much
better enhancement than in the portal-venous phase. The overall
tumor volume – defined as volumetric RECIST (vRECIST) – was
obtained on the basis of this segmentation (Figure 1, C and D). The
MR imaging scan obtained before contrast material administration
(Figure 1, E and F) was subtracted from the 20-second scan to remove
any background signal. This step is particularly important for the
assessment of lesions that may exhibit high signal intensity on pre-
contrast T1-weighted images due to hemorrhage with the presence of
methemoglobin and/or due to melanin as seen in some metastasis of
uveal melanoma [21,22]. The 3D segmentation mask was then
transposed onto this subtracted MR imaging scan. The average
enhancement values from the subtracted MR imaging scan used for
the quantitative volumetric tumor enhancement – defined as quan-
titative EASL (qEASL) – calculation were obtained as follows: a region
of interest (ROI) formed by 1 cm3 was placed in the normal appearing
liver parenchyma as a reference for normalization to calculate the
relative enhancement within the tumor (Figure 1, G and H). The
ROI was placed in the ipsilateral lobe of the evaluated lesion at a level
of section on which the lesion had its largest diameter and on the
extratumoral liver parenchyma identified as non-enhancing after
image subtraction. ROI placement was carefully performed to avoid
any adjacent main branch blood vessels, the gallbladder, liver
periphery, and motion artifacts. Viable (i.e., enhancing) tumor [13]
was defined as voxels within the 3D segmentation mask where the
enhancement was higher (defined as N2 standard deviation value of the
reference ROI) than that of the normal liver parenchyma. The volume
of viable tumor expressed in cubic centimeters (cm3) was measured for
each lesion [qEASL (cm3)] and also defined as a percentage of the total
tumor volume [qEASL (%)]. Subsequently, to visually demonstrate
viable tumor regions within the 3D segmentation mask based on the
previous ROI calculations, a color map with a blue-red scale was
automatically generated by the software (blue representing non-
enhancing necrotic tissue and red representing viable enhancing tumor
tissue; Figure 1, G and H). Further details of the technique are
presented in the Supplementary Materials.
Tumor Response Assessment and Overall Survival. Each patient
was classified as a responder or non-responder according to WHO,
RECIST, EASL, mRECIST, vRECIST, and qEASL criteria on the
basis of pretreatment and 3 to 4 weeks posttreatment MR imaging
results of the target and non-target lesions. Response categorization
for EASL, mRECIST, qEASL (cm3), and qEASL (%) was based on
arterial phase images. Because no guidelines exist for volumetric
tumor response criteria, we deliberately selected the same cutoff
values that are currently used in RECIST and mRECIST for
vRECIST and qEASL to unify and simplify response assessment in a
clinical setting. Thus, by using the formula: Volume = 4/3πr3, where
r is the radius and π is the mathematical constant representing the
ratio of a circle's circumference to its diameter, a decrease of 30%
defining partial response (PR) using the unidimensional RECIST and
mRECIST corresponds to a decrease of 65% of tumor volume.
Table 2 summarizes tumor response criteria.
Figure 1. Quantitative volumetric contrast-enhanced MR imaging assessment technique (qEASL). The left column represents baseline
MR imaging, and the right column represents the follow-upMR imaging after TACE. (a and b) The semiautomated tumor segmentation on
a representative contrast-enhanced T1-weighted MR sequence at the arterial phase. (c and d) The corresponding volume of the
segmented tumor in a 3D rendering. (e and f) The T1-weighted MR sequence before contrast administration to demonstrate baseline
background signal intensity of the tumors. (g and h) The qEASL color maps of the tumor on the subtracted MR imaging scan [the scan
before contrast material (E and F) was subtracted from the arterial phase scan (a and b) to remove any background signal intensity]. Color
maps: red represents maximum enhancement and blue represents no enhancement, normalized by the ROI. Green box: 3D ROI used as
the reference background of image intensity.
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The patients with objective response were classified as responders, and
the other patients [with stable disease (SD) and progressive disease
(PD)] were classified as non-responders. As no data exist for the
response assessment in uveal melanoma metastatic to the liver with
regard to the inclusion of target and non-target lesions, the final
response assessment was based on the target lesions alone and also
determined by incorporating the target and non-target lesion
responses (overall response) [10–12,14].Statistical Analysis
Data were summarized using descriptive statistics (count and
frequency for categorical variables and mean and range for continuous
variables). Significance levels and confidence intervals (CIs) were
calculated, when possible, with exact methods that do not rely on
normal approximations, to increase validity of the findings. A paired
Student's t test with its exact permutation distribution was used to
compare size, tumor volume, and tumor enhancement before and
after TACE to evaluate tumor response to treatment. To evaluate the
Table 2. Response Criteria
WHO RECIST EASL mRECIST vRECIST qEASL (cm3) qEASL (%)
CR Disappearance of all
target lesions
Disappearance of
all target lesions
Disappearance of all
enhancing tissue in all
target lesions
Disappearance of
all enhancing tissue
in all target lesions
Disappearance of
all target lesions
Disappearance of
all enhancing tissue
in all target lesions
Disappearance of
all enhancing tissue in
all target lesions
PR ≥50% decrease in the
sum of the product
of bidimensional
diameter of the
target lesions
≥30% decrease in the
sum of the longest
diameter of the
target lesions
≥50% decrease in the sum
of the product of
bidimensional diameter
of enhancing tissue of
the lesions
≥30% decrease in the
sum of the longest
enhancing diameter
of the target lesions
≥65% decrease in
the sum of the
volume of the
target lesions
≥65% decrease in
the sum of enhancing
tissue volume of
the lesions
≥65% decrease in
the sum of percentage
of enhancing tissue of
the lesions
PD ≥25% increase in the
sum of the product
of bidimensional diameter
of the target lesions
≥20% increase in the
sum of the longest
diameter of the
target lesions
≥25% increase in the
sum of the product of
bidimensional diameter
of the lesions
≥20% increase in
the sum of the
longest enhancing
diameter of the
target lesions
≥73% increase in
the sum of the
volume of the
target lesions
≥73% increase in
the sum of enhancing
tissue volume of
the lesions
≥73% increase in
the sum of percentage
of enhancing tissue of
the lesions
SD Any case that does not
qualify for either CR,
PR, or PD
Any case that does not
qualify for either CR, PR,
or PD
Any case that does
not qualify
for either CR, PR,
or PD
Any case that does
not qualify for
either CR, PR,
or PD
Any case that does
not qualify for
either CR, PR,
or PD
Any case that does
not qualify for either
CR, PR, or PD
Any case that
does not qualify
for either
CR, PR, or PD
Note: WHO is calculated by measuring the longest diameter of the tumor in the axial plane and by drawing a line perpendicular to it. EASL is calculated by measuring the longest diameter of the enhancing
tumor in the axial plane and by drawing a line perpendicular to it. mRECIST is calculated by measuring the longest diameter of the enhancing tumor in the axial plane. qEASL (cm3) is calculated by
measuring the volume of enhancing tumor. qEASL (%) is calculated by measuring the percentage of enhancing tumor in the lesion volume.
Table 3. Signal Intensities before and after TACE
Target Lesions Non-Target Lesions
Before
TACE
After
TACE
P Value Before
TACE
After
TACE
P Value
FS T2-weighted images
Hypointense relative to liver 0 (0) 0 (0) .367 1 (4) 0 (0) .250
Hyperintense relative to liver 21 (70) 17 (57) 21 (72) 18 (62)
Hyperintense relative to liver and spleen 9 (30) 13 (43) 7 (24) 11 (38)
SS T2-weighted images
Hypointense relative to liver 0 (0) 1 (3) .504 0 (0) 0 (0) .761
Hyperintense relative to liver 17 (57) 14 (47) 19 (66) 17 (59)
Hyperintense relative to liver and spleen 13 (43) 15 (50) 10 (34) 12 (41)
T1-weighted images
Isointense relative to liver 1 (3) 0 (0) .002 0 (0) 0 (0) .124
Hypointense relative to liver 23 (77) 11 (37) 25 (86) 20 (69)
Hyperintense relative to liver 6 (20) 19 (63) 4 (14) 9 (31)
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after TACE, the ratio of the sample proportion of “T2 = 2” and “T1 = 2”
in all target and non-target lesions before versus after treatment was
calculated. The significance level of this ratio was obtained as twice its tail
probability from its exact permutation distribution [23], where
permutations were performed, for each patient independently, between
the pretreatment and the posttreatment vector of the T2 and T1 signal
values of the target and non-target lesions. The overall survival was
calculated from the date of the first TACEuntil death.Themedian overall
survival of the entire cohort was estimated from the 50% point of the
Kaplan-Meier curve, and its standard error and 95% CI were obtained
using the jackknife technique. The predictive value of each response
criterion was evaluated on its own (univariate) and then in a multivariate
analysis. The univariate predictive value was evaluated by 1) the survival
curves for responders and non-responders using Kaplan-Meier; 2) Cox
proportional hazard ratios (HRs) between the curves of responders and
non-responders, whose significance level was calculated using the log-rank
test and its exact permutation distribution; and 3) the percent variance
(R2) in survival that is explained by the “response”/”non-response”
categorization. The 95% CIs for the HR between responders and non-
responders were calculated for every method using the exact inference
procedure for HRs [24], implemented with the algorithm for computing
exact CIs for odds ratios in conditional logistic regression (Georg Heinze
and Tobias Ladner (2013). logistiX: Exact logistic regression including
Firth correction. R package version 1.0-1). To minimize bias, R2 was
estimated by cross-validation. A multivariate analysis was explored by a
rule that selects the first predictor as the one that has the highest predictive
value of survival based on R2 and then including the next predictor if the
inclusion increases the predictive value. A difference with a two-tailed
P value of less than .05 was considered statistically significant. Statistical
analysis was performed with a software package (R: A Language and
Environment for Statistical Computing, R Core Team, R Foundation for
Statistical Computing, Vienna, Austria, 2013).
Results
Patient Data
Mean time from uveal melanoma diagnosis and liver metastasis was
103.4 ± 110.6 months (range, 3-424). Mean time from pretreatmentMR imaging to the first TACE was 2.2 ± 1.8 weeks (range, 0-7). Mean
time from the TACE to posttreatment MR imaging was 4 ± 1.3 weeks
(range, 3-7). Mean follow-up period was 13.5 ± 18.2 months (range,
.7-58.7). A mean of 2.9 ± 1.7 TACE (range, 1-6) was performed per
patient, for a total of 43 procedures. Four patients (26.7%)
underwent only one TACE session. After the first TACE, the
number of patients who underwent second, third, fourth, fifth, and
sixth session of TACE was 4 (26.7%), 1 (6.7%), 3 (20%), 2 (13.3%),
and 1 (6.7%), respectively. Thirteen TACE (86.7%) were performed
on the right lobe of the liver and 2 (13.3%) on the left. A total of 114
MR imaging studies were reviewed in this cohort (meanMR imaging
exam per patient, 7.6 ± 7.5; range, 2-27).
MR Imaging Data
Signal intensities. Signal intensities before and after TACE are
summarized in Table 3. On fat-suppressed T2-weighted fast spin-echo
sequences, there were no statistically significant differences in signal
intensity in target and non-target lesions before and after TACE (P = .367
and P = .25, respectively). Similar results were obtained on single-shot
T2-weighted sequences with no significant change in signal intensity
in target and non-target lesions before and after TACE (P = .504 and
P = .761, respectively). However, on T1-weighted images, target lesions
Table 4. Changes in Conventional and Volumetric Tumor Response Criteria in Target and Non-Target Lesions after TACE
Target Lesions Non-Target Lesions
Before TACE After TACE P Value Before TACE After TACE P Value
Conventional response criteria
WHO 55.4 cm2 (59.6) 60.6 cm2 (79.1) .526 8.7 cm2 (7.1) 11.2 cm2 (9) b.001
RECIST 7.5 cm (4.7) 7.8 cm (5.7) .594 3.2 cm (1.3) 3.7 cm (1.6) .006
EASL 33.4 cm2 (38.9) 36.9 cm2 (64.2) .701 5.1 cm2 (4.6) 7.9 cm2 (7.8) .003
mRECIST 6.4 cm (4.1) 6.3 cm (6) .878 2.6 cm (1.1) 3.1 cm (1.6) .008
Volumetric response criteria
vRECIST 297.2 cm3 (473.4) 409.5 cm3 (847.2) .244 15 cm3 (19.9) 20.5 cm3 (25.2) b.001
qEASL[cm3] 152.1 cm3 (240.6) 268.3 cm3 (644.8) .270 10.1 cm3 (15) 14.2 cm3 (17.5) .008
qEASL[%] 63.9 % (26.2) 42.6 % (33.8) .016 72.9 % (28.7) 72.4 % (27.9) .214
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TACE compared to the baseline MR imaging (P = .002), whereas this
was not the case for non-target lesions (P = .124).
Target and Non-Target Lesions. Table 4 summarizes the
pretreatment and 3 to 4 weeks posttreatment changes in conventional
tumor response criteria according to WHO, RECIST, EASL, and
mRECIST, as well as volumetric changes according to vRECIST and
qEASL in all target and non-target lesions. In target lesions, none of
the conventional tumor response criteria showed significant changes
after TACE. Likewise, the volume of enhancing tumor [qEASL
(cm3)] did not show any statistically significant difference (P = .270),
while the percentage of enhancing tumor [qEASL (%)] decreased
significantly (P = .016), reflecting tumor necrosis induced by TACE.
As opposed to the target lesions, non-target lesions showed
statistically significant increase in all conventional criteria as well as
in vRECIST and qEASL (cm3), while the percentage of enhancing
tumor [qEASL (%)] remained stable.
Tumor Response Criteria in Target and Non-Target Lesions
Table 5 summarizes the tumor response in all patients according to
target and non-target lesions. No new lesion appeared in the study
population between the pretreatment and 3 to 4 weeks posttreatment
MR imaging.
Overall Response
Conventional Response Criteria. When usingWHOmeasurements,
six patients (40%) had SD and the remaining nine patients (60%)
had PD. According to RECIST, eleven patients (73%) had SD and
four patients (27%) had PD. Thus, the use of both anatomic
conventional criteria did not classify any patients as responders afterTable 5. Tumor Response Assessment after the First TACE in Target and Non-Target Lesions
Target Lesion Non-Target Lesion
CR PR SD PD CR PR SD PD
Conventional response criteria
WHO 0 0 12 3 0 0 7 8
RECIST 0 0 13 2 0 0 12 3
EASL 1 5 3 6 0 1 3 11
mRECIST 1 4 8 2 0 0 10 5
Volumetric response criteria
vRECIST 0 0 13 2 0 0 9 6
qEASL (cm3) 0 5 8 2 0 0 8 7
qEASL (%) 0 5 9 1 0 0 15 0TACE and no comparative survival analysis between responders and
non-responders could be performed. When stratifying according to the
EASL guideline, one patient (7%) showed PR, one patient (7%) had
SD, and thirteen patients (86%) had PD. According tomRECIST, four
patients (27%) showed PR, five patients (33%) had SD, and six patients
(40%) had PD. The overall rate of responders was higher for mRECIST
as compared to EASL (27% and 7%, respectively).
Volumetric Response Criteria. When quantifying tumor response
with vRECIST, nine patients (60%) showed SD and six patients (40%)
showed PD. When using qEASL (cm3), four patients (26.7%) showed
PR, four patients (26.7%) had SD, and seven patients (46.6%) had PD.
As for qEASL (%), five patients (33.3%) showed PR, nine patients
(60%) had SD, and one patient (6.7%) had PD.
Survival Data
At the time of the redaction of the present study, all patients were
dead. The median overall survival of the entire cohort was 5.6 months
(95%CI = 2.6 months, 12.2 months). All patients were non-responders
using the anatomic criteria WHO, RECIST, and vRECIST; thus, no
stratification was possible and no survival data could be calculated. For
the remaining criteria, Figure 2 illustrates the survival analysis according
to the target lesion response and Figure 3 illustrates the survival analysis
according to overall response (target and non-target lesions). Whether
using the analysis based on target lesions or the overall response, there was
no significant difference in responders and non-responders as assessed
according to EASL and mRECIST (Table 6). However, quantitative
volumetric assessment according to qEASL (cm3) was the only criteria
that showed a significant difference in responders and non-responders
according to response based on target lesions with a median survival of
3.6 versus 40.5 months (HR = 0.00; 95% CI = 0.00-0.34; P b .001),
respectively, and according to overall response with a median survival of
4.4 versus 40.9 months (HR = 0.00; 95% CI = 0.00-0.4; P = .001),
respectively. qEASL (%) had the same responders based on target lesions
and on overall response assessment; it showed a trend but failed to reach
statistical significance (P = .052; Table 6). Statistical analyses also showed
that qEASL (cm3) had the highest value in predicting survival on its own
(R2 = 79%). Among all the analyses that added a second predictor, the
multivariateR2 was either lower than or equal to the one that had already
been achieved by qEASL (cm3) alone (results not shown).
Discussion
Themain finding of this study is that quantitative volumetric changes in
tumor enhancement (qEASL) accurately predicted response to therapy
and survival in patients with uveal melanoma after the first TACE.
Survival is the ultimate marker for treatment efficacy in solid
tumors, and radiologic objective response has been widely used and
Figure 2. Survival analysis based on target lesion response. (a–d) Survival analysis according to tumor response criteria [EASL,mRECIST, qEASL
(cm3), and qEASL (%)]. All patients were non-responders usingWHO, RECIST, and vRECIST criteria; thus, no survival data could be calculated.
Figure 3. Survival analysis based on overall patient response. (a–d) Survival analysis according to tumor response criteria [EASL,
mRECIST, qEASL (cm3), and qEASL (%)]. All patients were non-responders using WHO, RECIST, and vRECIST criteria; thus, no survival
data could be calculated.
Translational Oncology Vol. 7, No. 4, 2014 Quantifying Metastatic Uveal Melanoma 3D Response Duran et al. 453
Table 6. Survival Based on Target Lesions and Overall Patient Survival
Response Criteria Survival Based on Target Lesions Overall Patient Survival
Survival (Months) HR (95% CI) R2 (%) P Value Survival (months) HR (95% CI) R2 (%) P Value
WHO
R – 1 – – 1 –
NR 5.6 5.6
RECIST
R – 1 – – 1 –
NR 5.6 5.6
EASL
R 11.8 0.48 (0.12-1.63) 0 .252 4.4 2.26 (0.05-20.29) 0 .458
NR 2.8 6.4
mRECIST
R 8.6 0.96 (0.24-3.60) 0 .99 11.8 0.91 (0.20-3.46) 0 .882
NR 3.7 4.6
vRECIST
R – 1 – – 1 –
NR 5.6 5.6
qEASL (cm3)
R 40.5 0.00 (0.00-0.34) 66 b.001 40.9 0.00 (0.00-0.40) 79 .001
NR 3.6 4.4
qEASL (%)
R 29.5 0.27 (0.06-1.01) 18 .052 29.5 0.27 (0.06-1.01) 18 .052
NR 3.6 3.6
Note: R, responders; NR, non-responders; qEASL (%) had the same responders based on target lesions and on overall response assessments.
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traditionally used in clinical trials [9]. Because the prognosis of uveal
melanoma is highly dependent on disease progression in the liver, a
local therapy holds promise in managing this otherwise highly
chemoresistant disease. Hence, it is crucial to track the response to
therapy early in the course of treatment to prevent a loss of chance for
the patient.
Our study showed that conventional response criteria assessing
anatomic changes in the tumor (WHO, RECIST, and vRECIST)
failed to stratify patients according to the tumor response and to
predict survival. Moreover, while achieving stratification between
responders and non-responders, EASL and mRECIST failed to
predict survival, while qEASL was the only criteria predictive of
overall survival. These results collectively show that quantitative
volumetric tumor response assessing viable tumor is the optimal
tumor response criteria in patients with metastatic uveal melanoma to
the liver after the first session of TACE. This may be explained by the
fact that conventional tumor response criteria that measure the tumor
unidimensionally or bidimensionally wrongly assume that the tumor
proportionally grows or shrinks in a spherical manner. Indeed,
unidimensional and bidimensional tumor response criteria presume
that lesion diameter (RECIST), enhancing diameter (mRECIST),
and the product of diameters (WHO) or enhancing diameters (EASL)
correlate with the tumor volume. However, most liver tumors exhibit
asymmetrical and heterogeneous pattern of necrosis that challenge
precise tumor response assessment after chemoembolization [9].
However, by the nature of quantitative volumetric measurement
methods such as qEASL, these limitations may be overcome. Indeed,
qEASL has several methodological strengths: this approach utilizes a
semiautomatic tumor segmentation that evaluates the entire tumor
volume, including the viable enhancing as well as necrotic parts of the
tumor. Moreover, the semiautomatic approach of the software allows
for time efficient tumor segmentation while allowing for adjustments
by the radiologist [19]. This technique has been shown to be
reproducible between radiologic readers and its precision wasdemonstrated with a strong correlation with tumor necrosis as
measured on histopathology [20,25].
In contrast to most tumors, uveal melanoma liver metastasis may
be heterogeneous depicting high signal intensity on baseline
precontrast T1-weighted images due to hemorrhage with the
presence of methemoglobin and/or melanin [21,22]. Furthermore,
as shown by our results, uveal melanoma lesions treated with TACE
exhibited more high signal intensities on precontrast T1-weighted
images compared to baseline imaging, making oftentimes challeng-
ing the assessment of tumor enhancement, even when image
subtraction is used. This might explain why a quantitative
measurement may be more precise in assessing these lesions in
comparison to a more subjective method such as EASL, in that the
calculation of volume eliminates potential variability in the
assessment based on slice selection.
The aggressiveness of the disease with potential changes in non-
target lesions already seen in the short interval between the baseline
and after TACEMR imaging provided the rationale to investigate the
effect of the untreated lesions in the overall response. Our study
demonstrated that the analysis based on the target lesions provided
similar results as when including target and non-target lesions in the
assessment of early tumor response. This may potentially lead to
simplification of imaging assessment after one session of TACE.
There were several limitations to this study. First, the sample of the
study was relatively small. However, uveal melanoma is a rare disease,
and even in centers with high patient volume, it is unlikely to have a
large sample from a single institution. Thus, a multi-institutional
study with a larger cohort is needed to confirm our data. Moreover, a
thorough statistical analysis was performed including exact permu-
tation distribution in the calculations to overcome this limitation.
Second, this study included only patients with pretreatment and
posttreatment MR imaging, leading to a selection bias. However,
accumulation of iodized oil (as used in TACE) into treated lesions
limits the reliability of contrast enhancement on computed
tomography scans; thus, only contrast-enhanced MR imaging is
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quantitative volumetric measurements used in this study lack
radiologic-pathologic validation [20]. However, this is unrealistic as
patients with uveal melanoma metastatic to the liver were not
considered appropriate candidates for any surgical treatment and were
referred for TACE. Fourth, this study did not investigate the potential
role of quantitative volumetric diffusion-weighted MR imaging.
Diffusion-weighted MR imaging is increasingly used to evaluate
tumor response to therapy [26]. Buijs et al. [27] showed an increase in
conventional apparent diffusion coefficient values in liver metastasis
of uveal melanoma in patients undergoing several cycles of TACE.
3D quantitative apparent diffusion coefficient has shown promising
preliminary results [20]. Future work could investigate the role of this
novel technique alone or in combination with enhancement-based
methods in the response assessment of patients with uveal melanoma
metastatic to the liver.
In conclusion, the current analysis indicates that quantitative
volumetric tumor enhancement (qEASL) may be used as a surrogate
biomarker for the prediction of survival in patients with uveal
melanoma metastatic to the liver after one session of TACE.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.05.004.
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